New drug combo takes on advanced cancers in early trial
NCT ID NCT05708950
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested an experimental drug called KVA12123, given alone or with the immunotherapy Keytruda, in 40 adults with advanced solid tumors (like lung, breast, or colon cancer) that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Participants received the drug every two weeks and had regular scans and blood tests. Because this is a small, early study, it focuses on safety and dosing rather than proving the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KVA12123 (an experimental drug) and pembrolizumab (Keytruda, an immunotherapy)
What this could lead to
If successful, this could point toward a new treatment option for advanced cancers that have stopped responding to standard therapies.
What could go wrong
This is an early-phase trial with only 40 participants, so results may not apply broadly. The drug may not shrink tumors or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109, United States
-
Sarah Cannon Research Institute at Florida Cancer Specialists
Sarasota, Florida, 34232, United States
-
Sarah Cannon Research Institute at HealthONE
Denver, Colorado, 80218, United States
-
Sarah Cannon Research Institute at Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
-
UCLA Health (Santa Monica Cancer Care)
Santa Monica, California, 90404, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States